

**ATTORNEY DOCKET NO. 14014.0323U2  
PATENT**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims**

1. (previously presented) A method of delivering a nucleic acid to an alveolar cell, in vitro, comprising administering to the alveolar cell an AAV5 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

2. (currently amended) A method of delivering a nucleic acid to an alveolar cell in a subject comprising administering to the subject an AAV5 particle comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, wherein the ~~nucleic acid~~AAV5 particle is delivered intranasally, thereby delivering the nucleic acid to an alveolar cell in the subject.

3 - 10 (canceled)

11. (previously presented) The method of any of claims 1-2 and 12-17, wherein the AAV inverted terminal repeats are AAV5 terminal repeats.

12. (currently amended) A method of delivering a nucleic acid to an alveolar cell in a subject comprising administering to the subject an AAV5 particle comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, wherein the ~~nucleic acid~~AAV5 particle is delivered via aerosol, thereby delivering the nucleic acid to an alveolar cell in the subject.

13. (currently amended) A method of delivering a nucleic acid to an alveolar cell in a subject comprising administering to the subject an AAV5 particle comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, wherein the ~~nucleic acid~~ AAV5

**ATTORNEY DOCKET NO. 14014.0323U2  
PATENT**

particle is delivered via the airway, thereby delivering the nucleic acid to an alveolar cell in the subject.

14. (previously presented) A method of delivering a nucleic acid to a cerebellar cell, in vitro, comprising administering to the cerebellar cell an AAV5 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

15. (previously presented) A method of delivering a nucleic acid to a cerebellar cell in a subject comprising administering to the subject an AAV5 particle comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, wherein the AAV5 particle is delivered directly to the brain of the subject, thereby delivering the nucleic acid to a cerebellar cell in the subject.

16. (previously presented) A method of delivering a nucleic acid to an ependymal cell, in vitro comprising administering to the ependymal cell an AAV5 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to an ependymal cell.

17. (previously presented) A method of delivering a nucleic acid to an ependymal cell in a subject comprising administering to the subject an AAV5 particle comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, wherein the AAV5 particle is delivered directly to the brain of the subject, thereby delivering the nucleic acid to an ependymal cell in the subject.